These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22403810)

  • 1. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
    Goulden S; Sutcliffe F; Stevens A
    Lancet Oncol; 2012 Feb; 13(2):127-8. PubMed ID: 22403810
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
    Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilotinib and dasatinib first-line: are we ready for imatinib replacement?
    Breccia M; Alimena G
    Leuk Res; 2011 Sep; 35(9):1153-5. PubMed ID: 21353701
    [No Abstract]   [Full Text] [Related]  

  • 6. Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
    Cortes J; Kantarjian H
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S22-S30. PubMed ID: 18397678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies in controlling drug resistance in chronic myeloid leukemia.
    Frame D
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
    Santos FP; Ravandi F
    Leuk Lymphoma; 2009 Dec; 50 Suppl 2(0 2):16-26. PubMed ID: 20017607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of chronic myeloid leukemia].
    Kubuki Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
    Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
    Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [TKI therapy for CML].
    Ohnishi K
    Rinsho Ketsueki; 2011 Jul; 52(7):452-9. PubMed ID: 21821976
    [No Abstract]   [Full Text] [Related]  

  • 13. First-line therapy for chronic myeloid leukemia: Past, present, and future.
    Pavlovsky C; Kantarjian H; Cortes JE
    Am J Hematol; 2009 May; 84(5):287-93. PubMed ID: 19306355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing second-line therapy for chronic myeloid leukemia.
    Raja T
    Indian J Cancer; 2012; 49(1):46-56. PubMed ID: 22842168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
    Nagata Y; Fukuda S; Kobayashi T; Yamashita T; Ohashi K; Sakamaki H; Akiyama H
    Int J Hematol; 2010 Apr; 91(3):539-41. PubMed ID: 20191333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
    Saglio G; Hochhaus A; Goh YT; Masszi T; Pasquini R; Maloisel F; Erben P; Cortes J; Paquette R; Bradley-Garelik MB; Zhu C; Dombret H
    Cancer; 2010 Aug; 116(16):3852-61. PubMed ID: 20564086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
    Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
    Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
    Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
    Kantarjian HM; Cortes J; La Rosée P; Hochhaus A
    Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.